Experts Debate Role Of Public-Private Partnerships In Vaccine, Drug Development
GroundTruth Project/GlobalPost: In Ebola response, Big Pharma and public sector strive to make up for lost time
“…The delayed response [to Ebola] is an example of the diverging interests of public and private sectors when it comes to addressing a public health crisis, say experts from both sides. … Still, some experts question whether the public-private partnership model will be successful in making a vaccine available to the poorest populations. They caution that when private companies get involved in public health, profit motives could dictate who ultimately benefits from the drugs…” (Murray, 1/29).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.